Vir Biotechnology, Inc. Impairment of Long-Lived Assets Held-for-use
Vir Biotechnology, Inc. (VIR) reported Impairment of Long-Lived Assets Held-for-use of $7.66 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2024-02-26
- Vir Biotechnology, Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-12-31 was $188.00K.
- Vir Biotechnology, Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-09-30 was $2.11M.
- Vir Biotechnology, Inc. impairment of long-lived assets held-for-use for the quarter ending 2022-12-31 was $0.00.
- Vir Biotechnology, Inc. impairment of long-lived assets held-for-use for the quarter ending 2022-09-30 was $0.00.
- Vir Biotechnology, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $7.66M.
- Vir Biotechnology, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- Vir Biotechnology, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2023-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $2.30M derived: sum of 2 quarters · filed 2024-02-26 | $7.66M 10-K · filed 2024-02-26 | |
| 2023-09-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $7.47M 10-Q · filed 2023-11-03 | ||
| 2023-06-30 | $5.37M 10-Q · filed 2023-08-04 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $0.00 10-K · filed 2024-02-26 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-04 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |